Valley National Advisers’s Cardiol Therapeutics CRDL Stock Holding History

Valley National Advisers’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6K	Hold	5,000	–	–	﹤0.01%	663
2025 Q4	$4K	Hold	5,000	–	–	﹤0.01%	700
2025 Q3	$5K	Hold	5,000	–	–	﹤0.01%	650
2025 Q2	$6K	Hold	5,000	–	–	﹤0.01%	630
2025 Q1	$4K	Hold	5,000	–	–	﹤0.01%	656
2024 Q4	$6K	Hold	5,000	–	–	﹤0.01%	605
2024 Q3	$9K	Hold	5,000	–	–	﹤0.01%	531
2024 Q2	$10K	Hold	5,000	–	–	﹤0.01%	611
2024 Q1	$9K	Hold	5,000	–	–	﹤0.01%	657
2023 Q4	$4K	Hold	5,000	–	–	﹤0.01%	816
2023 Q3	$4K	Hold	5,000	–	–	﹤0.01%	724
2023 Q2	$5K	Hold	5,000	–	–	﹤0.01%	678
2023 Q1	$4K	Hold	5,000	–	–	﹤0.01%	692
2022 Q4	$3K	Hold	5,000	–	–	﹤0.01%	702
2022 Q3	$3K	Hold	5,000	–	–	﹤0.01%	733
2022 Q2	$6K	Hold	5,000	–	–	﹤0.01%	640
2022 Q1	$8K	Hold	5,000	–	–	﹤0.01%	627
2021 Q4	$9K	Buy	+5,000	New	+$13.8K	﹤0.01%	618

Other funds holding CRDL

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Valley National Advisers's CRDL Position: Q1 2026 in Review

Valley National Advisers held its Cardiol Therapeutics (CRDL) position steady in Q1 2026 at 5,000 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #663.

Valley National Advisers first reported a position in CRDL in Q4 2021 and has held it in 18 quarters since. The position peaked at $10K in Q2 2024. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

Valley National Advisers held 5,000 shares of Cardiol Therapeutics worth $6K as of Q1 2026.
Valley National Advisers left its Cardiol Therapeutics share count unchanged in Q1 2026.
Cardiol Therapeutics made up ﹤0.01% of Valley National Advisers's portfolio in Q1 2026, its #663 holding.
Valley National Advisers first reported a position in Cardiol Therapeutics in Q4 2021 and has held it in 18 quarters since.
Valley National Advisers's Cardiol Therapeutics position peaked at $10K in Q2 2024.
47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Valley National Advisers's 13F filing for Q1 2026, filed 15 Apr 2026.